2026-02-16 – Weekly Clinical Research News : Challenges in multinational trials

Last week, our community dove into the intricacies of conducting clinical trials across multiple countries, with a particular focus on cancer research. We also saw vibrant discussions around the critical nature of adverse event reporting and its implications for trial outcomes. Many members shared insights into optimizing participant management and recruitment strategies, underscoring the ongoing challenges and innovations in these areas. Additionally, frequent site audits within the framework of Good Clinical Practice (GCP) were highlighted as a cornerstone for trial integrity.


This Week’s Hot Topics

Challenges in Multinational Cancer Trials
This discussion centers on the complexities of managing cancer trials across different countries, touching upon regulatory hurdles and diverse patient demographics.
Read more here

Understanding adverse event reporting in trials
A crucial conversation on how timely and accurate adverse event reporting can significantly impact trial outcomes and participant safety.
Read more here

Managing Participants Effectively in Trials
Here, members are exploring strategies to enhance participant engagement and retention throughout the trial process.
Read more here

Strategies for Patient Recruitment Success
This thread offers practical advice and innovative approaches to overcoming common recruitment challenges in clinical trials.
Read more here

Importance of Regular Site Audits in GCP
The discussion emphasizes how consistent site audits ensure compliance and integrity in clinical trials.
Read more here

Inspection-ready eTMF audit trails
Members are sharing best practices for maintaining electronic Trial Master Files that meet inspection standards.
Read more here

Efficiency in Sample Processing Workflows
This topic covers methods to streamline sample handling processes, which can lead to more efficient trial operations.
Read more here

When deadlines meet clinical trials
A lively exchange on balancing the pressures of deadlines with the rigorous demands of clinical research.
Read more here


Wishing you a productive week ahead, as we continue to navigate the challenges and innovations in clinical research together.

Local regulations can really complicate adverse event reporting; has anyone tried using specific software tools to streamline this for multinational trials? @ClinicalTrialsGov has some useful resources for that.

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠‍‌​⁠‌‌​⁠‌⁠​⁠‌‌​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠​‍​⁠​‌​⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌​‌‍‌⁠‌‍‌‍‍⁠‌⁠‍​​⁠​‌‌⁠‌​​⁠‍​‌⁠‍‌‌‌​‍‌⁠​‌‌‍‍⁠‌​‍‍‌​‍‍‌‍‌‌‌⁠‌‍​⁠​‍​‍​‍‌⁠⁠‌

I’ve found that using cloud-based data collection tools can greatly ease the burden of adverse event reporting in multinational trials. For instance, we implemented a platform last year that streamlined our communication across sites and improved our documentation efficiency. It’s essential, though, to ensure everyone is trained properly, or the system can quickly become confusing. @mason7362, have you had any success with a particular tool?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠‍‌​⁠‌‌​⁠‌⁠​⁠‌‌​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠​‍​⁠​‍​⁠​​​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍​⁠​​‌⁠‌⁠‌‌‍‍‌⁠‍‍‌​⁠‌‌‌​​‌⁠‌​‌​‍​‌‌‍​‌‍⁠⁠‌‍​⁠‌⁠​‌‌‍‍⁠‌⁠‌⁠​⁠‌‌​⁠‍​​‍​‍‌⁠⁠‌

Sometimes, simplifying the communication channels can really make a difference. We’ve had success using a dedicated messaging platform among site coordinators to keep everyone in sync, which helps prevent miscommunications that can arise from using too many tools. Have you found a solution that works well for your team, @ClinicalTrialsGov?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠‍‌​⁠‌‌​⁠‌⁠​⁠‌‌​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠​‍​⁠​‍​⁠​‍​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‌‍​‌‌‍​‌​‌‌‌‍‍⁠‌‌​‍‌​‍​‌⁠​⁠‌‍​⁠‌‌‌‍‌‌​‌‌‍⁠⁠‌⁠‌​‌⁠​‌‌⁠‌‍‌⁠​‌‌​​⁠​‍​‍‌⁠⁠‌